The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage
Completed
Conditions studied: Atrial Fibrillation
In brief
This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct comparative safety and effectiveness studies of dabigatran and warfarin using real world data from Humana's health plan operations.
Key facts
- Study ID
- NCT02061748
- Run by
- Boehringer Ingelheim
- People needed
- 38499
- Starts
- 2014-10-28
- Expected to finish
- 2016-03-15
- Last updated by the study team
- 2017-06-08
Who can join
Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient must have at least one inpatient, one physician office visit, or one emergency room visit with a diagnosis of AF on the index date or during the pre-index period.
- Patients must be continuously enrolled in a health plan during the pre-index period
- Patient must have a prescription for dabigatran or warfarin
- Patient must be treatment naive from all oral anticoagulant (OAC) use prior to first OAC prescription
- Aged 18-89 years on the index date. The index date is defined as the date of the first OAC prescription
You may not qualify if…
- Diagnosis of hyperthyroidism during the pre-index period,
- Having claims for any of the following within 3 months prior to the first diagnosis of AF: cardiac surgery, pericarditis, myocarditis, pulmonary embolism.
- Any patients with at least one medical claim for valvular heart disease.
Where it is running
- Comprehensive Health Insights, Louisville — Louisville, Kentucky, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.